A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ESTEEM-2
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 17 Jun 2017 Results of pooled analysis from Esteem and Palace 1-3 Phase 3 Trials presented at the 18th Annual Congress of the European League Against Rheumatism
    • 14 Apr 2017 Results of a pooled safety analysis of apremilast in patients from two randomized trials (ESTEEM-1 and ESTEEM-2; n=1184), published in the Journal of the American Academy of Dermatology
    • 03 Mar 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top